Shaw, R. Reichen. 2005. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J. Pharm. Exp. Ther. 313:952-961.

[0073] 6. Blank, C., A. Luz, S. Bendigs, A. Erdmann, H. Wagner, and K. Heeg. 1997. Superantigen and endotoxin synergize in the induction of lethal shock. Eur. J. Immunol. 27:825-833.

[0074] 7. Blazar, B., R. P. A. Taylor, S. N. Sehgal, and D. A. Vallera. 1994. Rapamycin, a potent inhibitor of T cell function, prevents graft rejection in murine recipients of allogeneic T-cell depended donor marrow. Blood. 83:600-609.

[0075] 8. Chesney, P. J., J. P. Davis, W. K. Purday, P. J. Wand, and R. W. Chesney. 1981. Clinical manifestations of toxic shock syndrome. J. Am. Med. Assoc. 246:741-748.

[0076] 9. Choi, Y., B. Kotzin, L. Hernon, J. Callahan, P. Marrack, and J. Kappler. 1989. Interaction of *Staphyloccocus aureus* toxin "superantigens" with human T cells. Proc. Natl. Acad. Sci. USA. 86:8941-8945.

[0077] 10. Coenen, J. J., H. J. Koenen, E. van Rijssen, L. B. Hilbrands, and I. Joosten. 2006. Rapamycin, and not cyclosporin A, preserves the highly suppressive $CD27^+$ subset of human $CD4^+CD25^+$ regulatory T cells. Blood. 107, 1018-1023.

[0078] 11. Darenberg, J., B. Soderquist, B. H. Normark, and A. A. Norrby-Tegland. 2004. Differences in potency of intravenous polyspecific immunoglobin G against *streptoccocal* and *staphyloccocal* superantigen: implications for therapy of toxic shock syndrome. Clin. Infect. Dis. 38:836-842.

[0079] 12. Das, S., A. Haddadi, S. Veniamin, and J. Samuel. 2008. Delivery of rapamycin-loaded nanoparticle down regulates ICAM-1 expression and maintains an immunosuppressive profile in human $CD34^+$ progenitor-derived dendritic cells. J. Biomed. Mater. Res. A. 85:983-992.

[0080] 13. Erbay E. and J. Chen. 2001. The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. J. Biol. Chem. 276: 36079-36082.

[0081] 14. Flechner, S. M. 2009. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation. 87:S1-6.

[0082] 15. Fleischer, B., H. Schrezenmeier, and P. Conradt. 1989. T lymphocyte activation by *staphylococcal* enterotoxins: role of class II molecules and T cell surface structures. Cell Immunol. 120:92-101.

[0083] 16. Fraser, J. D., and T. Proft. 2007. The *Streptococcal* superantigens. In Superantigens: Molecular basis for their role in human diseases. Kotb, M.; Fraser, J. D., Ed; ASM Press, Washington, D.C. pp 3-20.

[0084] 17. Frost, P., Y. Shi, B. Hoang, J. Gera, and A. Lichtenstein. 2009. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol. Cancer Ther. 8:83-93.

[0085] 18. Gomez-Cambronero, J. 2003. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett. 550:94-100.

[0086] 19. Granville, C. A., N. Warfel, J. Tsurutani, M. C. Hollander, et. al. 2007. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin. Cancer Res. 13:2281-2289.

[0087] 20. Haxhinasto, S., D. Mathis, and C. Benoist. 2008. The AKT-mTOR axis regulates de novo differentiation of $CD4^+Foxp3^+$ cells. J. Exp. Med. 205:565-574.

[0088] 21. Heitman, J., N. R. Movva, and M. N Hall. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 253:905-909.

[0089] 22. Holmberg, S. D, and P. A. Blake. 1984. *Staphylococcal* food poisoning in the United States. New facts and old misconceptions. J. Am. Med. Assoc. 251: 487-489.

[0090] 23. Huzella, L. M., M. J. Buckley, D. A. Alves, B. G. Stiles, and T. Krakauer. 2009. Central roles for IL-2 and MCP-1 following intranasal exposure to SEB: A new mouse model. Res. Vet. Sci. 86:241-247.

[0091] 24. Koehl, G. E., J. Andrassy, M. Guba, S. Richter, A. Kroemer, M. N. Scherer, M. Steinbauer, C. Graeb, H. J. Schlitt, K.-W. Jauch, E. K. Geissler. 2004. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 77:1319-1326.

[0092] 25. Kotzin, B. L., D. Y. M. Leung, J. Kappler, and P. A. Marrack. 1993. Superantigens and their potential role in human disease. Adv. Immunol. 54:99-166.

[0093] 26. Krakauer, T. 1994 Inhibition of toxic shock syndrome toxin-induced cytokine production and T cell activation by interleukin 10, interleukin 4, and dexamethasone. J. Infect. Dis. 172:988-992.

[0094] 27. Krakauer, T. 1999. The induction of CC chemokines in human peripheral blood mononuclear cells by *staphylococcal* exotoxins and its prevention by pentoxifylline. J. Leukco. Biol. 66:158-164.

[0095] 28. Krakauer, T. 1999. Immune response to *Staphylococcal* superantigens. Immunol. Res. 20:163-173.

[0096] 29. Krakauer, T. and M. Buckley. 2006. Dexamethasone attenuates *Staphylococcal* Enterotoxin B-induced hypothermic response and protects mice from superantigen-induced toxic shock. Antimicrob. Agents Chemother. 50:391-395.

[0097] 30. Krakauer, T. 2007. Small nonpeptide inhibitors of *Staphylococcal* superantigen-induced cytokine production and toxic shock. In Superantigens: Molecular basis for their role in human diseases. Kotb, M.; Fraser, J. D., Ed; Asm Press, Washington, D.C. pp 229-224.

[0098] 31. Krakauer, T., J. Stephens, M. Buckley, and M. Tate. 2007. Superantigen-induced cytokine release from whole-blood cell culture as a functional measure of drug efficacy after oral dosing in nonhuman primates. Res. In Vet. Sci. 83:182-187.

[0099] 32. Leclaire, R. D., R. E. Hunt, and S. Bavari. 2002. Protection against bacterial superantigen *staphylococcal* enterotoxin B by passive vaccination. Infect. Immun. 70:2278-2281.

[0100] 33. Levy, R., I. Nasie, D. Hillman, G. Arad, and R. Kaempfer. 2007. Broad-spectrum peptide antagonists of superantigen toxins. In Superantigens: Molecular basis for their role in human diseases, Kotb, M.; Fraser, J. D., Ed; ASM Press, Washington, D.C. pp 217-227.